Switching statins: NICE tool overestimates benefits of statinsBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7556.1512-b (Published 22 June 2006) Cite this as: BMJ 2006;332:1512
- D Graham Mackenzie, specialist registrar in public health (email@example.com)
- Public Health Department, NHS Fife, Windygates, Fife KY8 5RG
EDITOR—Moon and Bogle should be supported in their call to move from branded to generic statins.1 However, by using the costing tool of the National Institute for Health and Clinical Excellence (NICE),2 they have probably overestimated the benefits of statins.
The 10 year risk thresholds for cardiovascular disease for starting a statin in primary prevention have recently been reduced from 40% to 20%. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial